REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – The experimental oral therapy BG-12 (dimethyl fumarate) appears to be effective in reducing relapses and disability progression, according to the results of the phase III DEFINE study (Gold et al. ECTRIMS 2011; abstract 95).